313 related articles for article (PubMed ID: 27853367)
1. Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells.
Shi D; Liu Y; Xi R; Zou W; Wu L; Zhang Z; Liu Z; Qu C; Xu B; Wang X
Int J Nanomedicine; 2016; 11():5823-5835. PubMed ID: 27853367
[TBL] [Abstract][Full Text] [Related]
2. Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Wang T; Wen T; Li H; Han B; Hao S; Wang C; Ma Q; Meng J; Liu J; Xu H
Int J Nanomedicine; 2019; 14():5581-5594. PubMed ID: 31413564
[TBL] [Abstract][Full Text] [Related]
3. Autophagy enhanced antitumor effect in K562 and K562/ADM cells using realgar transforming solution.
Wang X; Chen B; Zhao L; Zhi D; Hai Y; Song P; Li Y; Xie Q; Inam U; Wu Z; Yu L; Li H
Biomed Pharmacother; 2018 Feb; 98():252-264. PubMed ID: 29272786
[TBL] [Abstract][Full Text] [Related]
4. Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution.
Wang X; Zhang X; Xu Z; Wang Z; Yue X; Li H
Biol Pharm Bull; 2013; 36(4):641-8. PubMed ID: 23358330
[TBL] [Abstract][Full Text] [Related]
5. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
7. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
8. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
9. Apoptotic effect of As2S2 on K562 cells and its mechanism.
Li JE; Wu WL; Wang ZY; Sun GL
Acta Pharmacol Sin; 2002 Nov; 23(11):991-6. PubMed ID: 12421474
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
[TBL] [Abstract][Full Text] [Related]
11. [Apoptosis effects of drug sensitivity leukemia cells induced by nano-realgar].
Wang YS; Zhou ST; Wei HL
Zhongguo Zhong Yao Za Zhi; 2013 Jul; 38(13):2202-5. PubMed ID: 24079254
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
[TBL] [Abstract][Full Text] [Related]
13. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
Tan Z; Peng A; Xu J; Ouyang M
BMC Anesthesiol; 2017 Sep; 17(1):132. PubMed ID: 28962554
[TBL] [Abstract][Full Text] [Related]
14. Acetylshikonin induces apoptosis of human leukemia cell line K562 by inducing S phase cell cycle arrest, modulating ROS accumulation, depleting Bcr-Abl and blocking NF-κB signaling.
Hao G; Zhai J; Jiang H; Zhang Y; Wu M; Qiu Y; Fan C; Yu L; Bai S; Sun L; Yang Z
Biomed Pharmacother; 2020 Feb; 122():109677. PubMed ID: 31810012
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Zhu X; Li Y; Luo X; Fei J
Cell Signal; 2012 Jun; 24(6):1134-40. PubMed ID: 22330069
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.
Shinohara H; Taniguchi K; Kumazaki M; Yamada N; Ito Y; Otsuki Y; Uno B; Hayakawa F; Minami Y; Naoe T; Akao Y
Cancer Lett; 2015 Apr; 360(1):28-38. PubMed ID: 25644089
[TBL] [Abstract][Full Text] [Related]
17. Realgar (As4S4) nanoparticles and arsenic trioxide (As2O3) induced autophagy and apoptosis in human melanoma cells in vitro.
Pastorek M; Gronesova P; Cholujova D; Hunakova L; Bujnakova Z; Balaz P; Duraj J; Lee TC; Sedlak J
Neoplasma; 2014; 61(6):700-9. PubMed ID: 25150315
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
19. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
20. Nano-realgar suppresses lung cancer stem cell growth by repressing metabolic reprogramming.
Yang FR; Zhao YF; Hu XW; Liu ZK; Yu XD; Li CY; Li XR; Li HJ
Gene; 2021 Jul; 788():145666. PubMed ID: 33887368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
